Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Technetium Tc99m etarfolatide

Drug Profile

Technetium Tc99m etarfolatide

Alternative Names: 99mTC-Etarfolatide; EC 145 companion diagnostic - Endocyte; EC-20; Etarfolatide; Etarfolatide TC99m; Folate-Tc99m; FolateScan; FOLCEPRI; In 111-EC20; NMK 20; Tc 99m-EC20; Vintafolide companion diagnostic

Latest Information Update: 28 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Endocyte
  • Developer Endocyte; Nihon Medi-Physics
  • Class Imaging agents; Radiopharmaceutical diagnostics
  • Mechanism of Action Single-photon emission-computed tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer; Pituitary cancer; Renal cell carcinoma
  • Preregistration Submission Withdrawal Ovarian cancer
  • No development reported Solid tumours
  • Discontinued Inflammation

Most Recent Events

  • 28 Feb 2019 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in USA (IV)
  • 21 Dec 2018 Endocyte has been acquired by Novartis
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top